The use of immunohistochemistry for diagnosis of prostate cancer

PURPOSE: Atypical glands (ASAP) are diagnosed in 5.0% of prostate biopsies, and cancer identification in a rebiopsy is higher than 40.0%. The use of antibodies to mark basal cells is currently a common practice, in order to avoid rebiopsies. There has been no reported study that has reviewed characteristics of radical prostatectomies (RPs) when immunohistochemistry (IHC) was necessary for definitive diagnosis. MATERIALS AND METHODS: Out of 4127 biopsies examined from 2004 to 2008, 144 (3.5%) were diagnosed with ASAP. IHC was performed using antibody anti-34ßE12 and p63. The results of surgical specimens of 27 patients treated by RP after the diagnosis of prostate cancer (PC) was made using IHC (Group 1) were compared with 1040 patients where IHC was not necessary (Group 2). RESULTS: IHC helped to diagnose PC in 103 patients (71.5%). Twenty-seven (26.2%) underwent RP. In Group 1, two (7.4%) adenocarcinomas were insignificant versus 29 (2.9%) for Group 2. Patients from Group 1 were younger (p = 0.039), had lower Gleason scores (GS) (p < 0.001), lower percentage of Gleason pattern 4 (p < 0.001), and smaller tumors (p < 0.001). CONCLUSION: The use of IHC did not lead to diagnosis of insignificant tumors as illustrated by absence of differences in pathological stage or positive surgical margins in men submitted to RP. Therefore, our results suggest that this modality should be routinely used for a borderline biopsy and ASAP cases.

Saved in:
Bibliographic Details
Main Authors: Leite,Katia R. M., Srougi,Miguel, Sanudo,Adriana, Dall’Oglio,Marcos F., Nesrallah,Adriano, Antunes,Alberto A., Cury,Jose, Camara-Lopes,Luiz H.
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Urologia 2010
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000500008
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1677-55382010000500008
record_format ojs
spelling oai:scielo:S1677-553820100005000082010-12-06The use of immunohistochemistry for diagnosis of prostate cancerLeite,Katia R. M.Srougi,MiguelSanudo,AdrianaDall’Oglio,Marcos F.Nesrallah,AdrianoAntunes,Alberto A.Cury,JoseCamara-Lopes,Luiz H. prostatic neoplasms diagnosis biopsy immunohistochemistry atypical small acinar proliferation PURPOSE: Atypical glands (ASAP) are diagnosed in 5.0% of prostate biopsies, and cancer identification in a rebiopsy is higher than 40.0%. The use of antibodies to mark basal cells is currently a common practice, in order to avoid rebiopsies. There has been no reported study that has reviewed characteristics of radical prostatectomies (RPs) when immunohistochemistry (IHC) was necessary for definitive diagnosis. MATERIALS AND METHODS: Out of 4127 biopsies examined from 2004 to 2008, 144 (3.5%) were diagnosed with ASAP. IHC was performed using antibody anti-34ßE12 and p63. The results of surgical specimens of 27 patients treated by RP after the diagnosis of prostate cancer (PC) was made using IHC (Group 1) were compared with 1040 patients where IHC was not necessary (Group 2). RESULTS: IHC helped to diagnose PC in 103 patients (71.5%). Twenty-seven (26.2%) underwent RP. In Group 1, two (7.4%) adenocarcinomas were insignificant versus 29 (2.9%) for Group 2. Patients from Group 1 were younger (p = 0.039), had lower Gleason scores (GS) (p < 0.001), lower percentage of Gleason pattern 4 (p < 0.001), and smaller tumors (p < 0.001). CONCLUSION: The use of IHC did not lead to diagnosis of insignificant tumors as illustrated by absence of differences in pathological stage or positive surgical margins in men submitted to RP. Therefore, our results suggest that this modality should be routinely used for a borderline biopsy and ASAP cases.info:eu-repo/semantics/openAccessSociedade Brasileira de UrologiaInternational braz j urol v.36 n.5 20102010-10-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000500008en10.1590/S1677-55382010000500008
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Leite,Katia R. M.
Srougi,Miguel
Sanudo,Adriana
Dall’Oglio,Marcos F.
Nesrallah,Adriano
Antunes,Alberto A.
Cury,Jose
Camara-Lopes,Luiz H.
spellingShingle Leite,Katia R. M.
Srougi,Miguel
Sanudo,Adriana
Dall’Oglio,Marcos F.
Nesrallah,Adriano
Antunes,Alberto A.
Cury,Jose
Camara-Lopes,Luiz H.
The use of immunohistochemistry for diagnosis of prostate cancer
author_facet Leite,Katia R. M.
Srougi,Miguel
Sanudo,Adriana
Dall’Oglio,Marcos F.
Nesrallah,Adriano
Antunes,Alberto A.
Cury,Jose
Camara-Lopes,Luiz H.
author_sort Leite,Katia R. M.
title The use of immunohistochemistry for diagnosis of prostate cancer
title_short The use of immunohistochemistry for diagnosis of prostate cancer
title_full The use of immunohistochemistry for diagnosis of prostate cancer
title_fullStr The use of immunohistochemistry for diagnosis of prostate cancer
title_full_unstemmed The use of immunohistochemistry for diagnosis of prostate cancer
title_sort use of immunohistochemistry for diagnosis of prostate cancer
description PURPOSE: Atypical glands (ASAP) are diagnosed in 5.0% of prostate biopsies, and cancer identification in a rebiopsy is higher than 40.0%. The use of antibodies to mark basal cells is currently a common practice, in order to avoid rebiopsies. There has been no reported study that has reviewed characteristics of radical prostatectomies (RPs) when immunohistochemistry (IHC) was necessary for definitive diagnosis. MATERIALS AND METHODS: Out of 4127 biopsies examined from 2004 to 2008, 144 (3.5%) were diagnosed with ASAP. IHC was performed using antibody anti-34ßE12 and p63. The results of surgical specimens of 27 patients treated by RP after the diagnosis of prostate cancer (PC) was made using IHC (Group 1) were compared with 1040 patients where IHC was not necessary (Group 2). RESULTS: IHC helped to diagnose PC in 103 patients (71.5%). Twenty-seven (26.2%) underwent RP. In Group 1, two (7.4%) adenocarcinomas were insignificant versus 29 (2.9%) for Group 2. Patients from Group 1 were younger (p = 0.039), had lower Gleason scores (GS) (p < 0.001), lower percentage of Gleason pattern 4 (p < 0.001), and smaller tumors (p < 0.001). CONCLUSION: The use of IHC did not lead to diagnosis of insignificant tumors as illustrated by absence of differences in pathological stage or positive surgical margins in men submitted to RP. Therefore, our results suggest that this modality should be routinely used for a borderline biopsy and ASAP cases.
publisher Sociedade Brasileira de Urologia
publishDate 2010
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000500008
work_keys_str_mv AT leitekatiarm theuseofimmunohistochemistryfordiagnosisofprostatecancer
AT srougimiguel theuseofimmunohistochemistryfordiagnosisofprostatecancer
AT sanudoadriana theuseofimmunohistochemistryfordiagnosisofprostatecancer
AT dallogliomarcosf theuseofimmunohistochemistryfordiagnosisofprostatecancer
AT nesrallahadriano theuseofimmunohistochemistryfordiagnosisofprostatecancer
AT antunesalbertoa theuseofimmunohistochemistryfordiagnosisofprostatecancer
AT curyjose theuseofimmunohistochemistryfordiagnosisofprostatecancer
AT camaralopesluizh theuseofimmunohistochemistryfordiagnosisofprostatecancer
AT leitekatiarm useofimmunohistochemistryfordiagnosisofprostatecancer
AT srougimiguel useofimmunohistochemistryfordiagnosisofprostatecancer
AT sanudoadriana useofimmunohistochemistryfordiagnosisofprostatecancer
AT dallogliomarcosf useofimmunohistochemistryfordiagnosisofprostatecancer
AT nesrallahadriano useofimmunohistochemistryfordiagnosisofprostatecancer
AT antunesalbertoa useofimmunohistochemistryfordiagnosisofprostatecancer
AT curyjose useofimmunohistochemistryfordiagnosisofprostatecancer
AT camaralopesluizh useofimmunohistochemistryfordiagnosisofprostatecancer
_version_ 1756428076995051520